These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

676 related items for PubMed ID: 19808140

  • 1. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G, Armirotti A, Nicodemo M, Cavallini L, Damonte G, Vannozzi MO, Venturini M.
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
    Boni J, Abbas R, Leister C, Burns J, Jordan R, Hoffmann M, DeMaio W, Hug B.
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):263-70. PubMed ID: 19015855
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.
    J Clin Oncol; 2007 Sep 01; 25(25):3958-64. PubMed ID: 17761980
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK.
    Clin Cancer Res; 2006 Oct 01; 12(19):5755-63. PubMed ID: 17020981
    [Abstract] [Full Text] [Related]

  • 7. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S, Thompson JA.
    Adv Ther; 2009 Jan 01; 26(1):55-67. PubMed ID: 19172239
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec 01; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec 01; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 01; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 14. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
    Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM.
    Pediatr Transplant; 2004 Apr 01; 8(2):151-60. PubMed ID: 15049795
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
    Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP.
    J Clin Oncol; 2004 Jun 15; 22(12):2336-47. PubMed ID: 15136596
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Temsirolimus in patients with renal cancer on hemodialysis.
    Lunardi G, Vannozzi MO, Armirotti A, Nicodemo M, Venturini M, Cavallini L.
    J Clin Oncol; 2008 Dec 01; 26(34):5652-3; author reply 5653-4. PubMed ID: 18981458
    [No Abstract] [Full Text] [Related]

  • 19. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec 01; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 20. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A, Figlin RA.
    Cancer; 2009 Aug 15; 115(16):3618-30. PubMed ID: 19479976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.